Clinical trial
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable…
NCT00362102 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00362102 |
|---|---|
| Title | A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma |
| Official title | A Multi-center, Open Label, Non-randomized, Phase II Study to Assess the Activity and Safety of Cetuximab Plus Irinotecan in Subjects With EGFR-detectable Metastatic Colorectal Carcinoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Carcinoma |
| Intervention type | Drug |
| Interventions | Cetuximab |
| Enrollment | 38 |
| Start date | Oct 1, 2005 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Aug 9, 2006 |
| Last update posted | Nov 22, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: